Information Provided By:
Fly News Breaks for December 7, 2015
BLUE
Dec 7, 2015 | 07:43 EDT
Jefferies analyst Gena Wang said the LentiGlobin update provided by bluebird bio at the ASH meeting showed modest efficacy in sickle cell disease beta-thalassemia and suggests the needs for further improvement in protocol, which could delay the program by one year or longer. Wang also said updates on the BCMA programs in multiple myeloma showed "promising progress," but noted that potential competitors exist in that space. The analyst keeps a Buy rating on bluebird but lowered her price target on shares to $96 from $108 following the ASH updates.